Rafferty Asset Management LLC Has $784,000 Position in Taysha Gene Therapies, Inc. $TSHA

Rafferty Asset Management LLC increased its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 102.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 239,785 shares of the company’s stock after purchasing an additional 121,102 shares during the period. Rafferty Asset Management LLC owned 0.09% of Taysha Gene Therapies worth $784,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. ST Germain D J Co. Inc. lifted its position in Taysha Gene Therapies by 81.8% during the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after purchasing an additional 4,333 shares during the period. Marex Group plc acquired a new position in Taysha Gene Therapies in the second quarter valued at approximately $29,000. E Fund Management Co. Ltd. bought a new position in Taysha Gene Therapies in the second quarter valued at approximately $31,000. Allegheny Financial Group bought a new position in Taysha Gene Therapies in the third quarter valued at approximately $49,000. Finally, R Squared Ltd acquired a new stake in Taysha Gene Therapies during the 3rd quarter worth $53,000. 77.70% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Sean P. Nolan sold 136,789 shares of the firm’s stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $649,747.75. Following the completion of the sale, the chief executive officer owned 2,949,569 shares in the company, valued at approximately $14,010,452.75. This trade represents a 4.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $4.71, for a total transaction of $942,000.00. Following the completion of the transaction, the insider owned 1,006,439 shares in the company, valued at approximately $4,740,327.69. This trade represents a 16.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 598,623 shares of company stock worth $2,822,188. Company insiders own 3.78% of the company’s stock.

Taysha Gene Therapies Price Performance

Shares of NASDAQ TSHA opened at $4.57 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. The business has a 50-day moving average of $4.79 and a 200-day moving average of $4.43. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -13.85 and a beta of 1.02. Taysha Gene Therapies, Inc. has a fifty-two week low of $1.05 and a fifty-two week high of $6.02.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Raymond James Financial restated a “strong-buy” rating and issued a $13.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. Wells Fargo & Company increased their target price on Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Monday, December 29th. The Goldman Sachs Group set a $11.00 target price on Taysha Gene Therapies in a research report on Thursday, December 4th. Finally, UBS Group set a $11.00 price target on Taysha Gene Therapies in a research note on Thursday, December 4th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.91.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.